福安药业：子公司庆余堂获头孢托仑匹酯颗粒药品注册证书

Core Viewpoint - The announcement indicates that the wholly-owned subsidiary of Fu'an Pharmaceutical, Qingyutang, has received a drug registration certificate from the National Medical Products Administration for a new product, which is expected to enhance the company's product line and market competitiveness [1] Group 1: Product Registration - The drug name is Cefotaxime Sodium Granules, classified as a Category 4 chemical drug, with specifications of 50mg and 30mg [1] - The approval numbers for the drug are National Drug Approval Code H20256029 and H20256028 [1] - Currently, only two companies have passed the consistency evaluation or are deemed to have passed it for this drug [1] Group 2: Market Impact - The acquisition of the drug registration certificate will enrich the subsidiary's product line and improve its market competitiveness [1] - However, the production and sales situation of the product, as well as its specific impact on the company's performance, remain uncertain due to industry policies and market environment changes [1]